grepcent public filings, reorganized for comparison

Surgery Partners, Inc. (SGRY)

CIK: 0001638833. SIC: 8062 Services-General Medical & Surgical Hospitals, NEC. Latest 10-K as of: 2026-03-02.

SIC breadcrumb: Services > SIC Major Group 80 > SIC 8062 Services-General Medical & Surgical Hospitals, NEC

SEC company page: https://www.sec.gov/edgar/browse/?CIK=1638833. Latest filing source: 0001638833-26-000008.

Informational only. Descriptive public-record data — not a rating, forecast, or investment advice. See Disclaimer.

At a glance

FY2025 · period end 2025-12-31 · filed 2026-03-02 · accession 0001638833-26-000008 · source: SEC companyfacts

Revenue
3,308,700,000 USD verified
Net income
-77,900,000 USD verified
Assets
8,119,700,000 USD verified
Free cash flow
195,600,000 USD computed
Net margin
-2.35% computed
Operating margin
11.77% computed
Revenue YoY
+6.24% computed
ROE
-4.55% computed

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Operating margin = operating income ÷ revenue. Revenue YoY = FY2025 revenue ÷ FY2024 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity.

No market price, no rating, no forecast on this site. Not investment advice.

Peer & cluster context

Peer percentile fingerprint

SGRY ratios vs SIC peers. Source: grepcent computed from latest SEC companyfacts ratios; peer set SIC major-group 80; per-ratio N printed.SGRY ratios vs SIC peers. Source: grepcent computed from latest SEC companyfacts ratios; peer set SIC major-group 80; per-ratio N printed.RatioSGRYPeer medianPercentileNNet margin-2.4%3.2%3556Operating margin11.8%5.5%8251Revenue growth6.2%11.8%3257FCF margin5.9%5.4%5148ROE-4.5%7.9%3753ROA-1.0%2.8%3958Liabilities / equity3.741.138154Current ratio1.871.636158

Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC major-group 80 SIC Major Group 80, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking.

Selected Fundamentals

MetricValueUnitFYFiled
Revenue3,308,700,000USD20252026-03-02
Net income-77,900,000USD20252026-03-02
Assets8,119,700,000USD20252026-03-02

Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-03-02. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001638833.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

Download these verified figures (annual + quarterly, with per-value filing provenance): JSON · CSV

Flow metrics use full-year FY periods from 10-K/10-K/A filings; balance-sheet metrics use FY-end instants. Free cash flow = operating cash flow - capital expenditures. Missing metrics are omitted rather than fabricated.

Metric20152016201720182019202020212022202320242025
Revenue1,145,438,000460,346,0001,771,500,0001,831,400,0001,860,100,0002,225,100,0002,539,300,0002,743,300,0003,114,300,0003,308,700,000
Net income1,429,0009,453,000-205,700,000-74,800,000-116,100,000-70,900,000-54,600,000-11,900,000-168,100,000-77,900,000
Operating income144,754,000196,482,00077,800,000235,900,000183,000,000302,200,000345,200,000328,000,000348,800,000389,500,000
Diluted EPS0.040.20-4.96-2.29-3.19-1.12-0.59-0.09-1.33-0.61
Operating cash flow84,481,000125,239,000144,600,000129,500,000246,900,00087,100,000158,800,000293,800,000300,100,000274,300,000
Capital expenditures33,439,00039,109,00039,800,00073,600,00042,900,00057,600,00080,600,00088,800,00090,400,00078,700,000
Assets2,304,958,0004,622,773,0004,676,300,0005,018,900,0005,413,200,0006,117,600,0006,682,100,0006,876,700,0007,890,000,0008,119,700,000
Stockholders' equity9,677,000654,731,000404,600,000296,800,000115,600,0001,089,000,0001,998,200,0001,987,200,0001,789,700,0001,712,900,000
Cash and cash equivalents69,699,000174,914,000184,300,00092,700,000317,900,000389,900,000282,900,000195,900,000269,500,000239,900,000
Free cash flow51,042,00086,130,000104,800,00055,900,000204,000,00029,500,00078,200,000205,000,000209,700,000195,600,000

Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

Metric20152016201720182019202020212022202320242025
Net margin0.83%-11.61%-4.08%-6.24%-3.19%-2.15%-0.43%-5.40%-2.35%
Operating margin17.15%4.39%12.88%9.84%13.58%13.59%11.96%11.20%11.77%
Return on equity97.69%-50.84%-25.20%-100.43%-6.51%-2.73%-0.60%-9.39%-4.55%
Return on assets0.41%-4.40%-1.49%-2.14%-1.16%-0.82%-0.17%-2.13%-0.96%
Liabilities / equity6.0610.5615.9145.834.622.342.463.413.74
Current ratio1.941.861.681.321.441.761.871.711.791.87

Industry Peer Context

Each number-line places SGRY against the min, median, and max of latest reported values among companies in the same SIC industry when at least three peers report that ratio.

Net margin peer context

SGRY Net margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8062; peer count 6.SGRY Net margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8062; peer count 6.6 SIC peersMin -2.4%Median 6.3%Max 11.1%SGRY -2.4%

Operating margin peer context

SGRY Operating margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8062; peer count 4.SGRY Operating margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8062; peer count 4.4 SIC peersMin 11.5%Median 11.8%Max 16.5%SGRY 11.8%

ROE peer context

SGRY ROE versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8062; peer count 4.SGRY ROE versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8062; peer count 4.4 SIC peersMin -4.5%Median 15.5%Max 56.1%SGRY -4.5%

ROA peer context

SGRY ROA versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8062; peer count 6.SGRY ROA versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8062; peer count 6.6 SIC peersMin -1.0%Median 5.9%Max 11.2%SGRY -1.0%

Financial Bridges

Waterfall figures reconcile reported SEC companyfacts components. Missing bridges are omitted when required components are not present for the same fiscal year.

Free cash flow = operating cash flow - capital expenditures

SGRY FY2025 free cash flow bridge from reported figures.SGRY FY2025 free cash flow bridge from reported figures.SGRY free cash flow bridgeFY2025: operating cash flow less capital expendituresSource: SEC companyfacts FY2025.Free cash flow bridgeReported amount$0.0B$250.0M$500.0M$274.3MOperating cash flow-$78.7MCapex$195.6MFree cash flow

Figure provenance: SEC companyfacts FY 2025. Operating cash flow: accession 0001638833-26-000008; concept NetCashProvidedByUsedInOperatingActivities; source concepts us-gaap:NetCashProvidedByUsedInOperatingActivities | Capital expenditures: accession 0001638833-26-000008; concept PaymentsToAcquirePropertyPlantAndEquipment; source concepts us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | Free cash flow: accession 0001638833-26-000008; concept NetCashProvidedByUsedInOperatingActivities - PaymentsToAcquirePropertyPlantAndEquipment; source concepts us-gaap:NetCashProvidedByUsedInOperatingActivities; us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

Financial Charts

SGRY revenue, last 5 periods. Source: SEC companyfacts FY2025.SGRY revenue, last 5 periods. Source: SEC companyfacts FY2025.SGRY RevenueLatest point: FY2025 = $3.3BSource: SEC companyfacts FY2025.Fiscal yearReported revenue$0.0B$2.0B$4.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001638833-26-000008; filed 2026-03-02. Concept: RevenueFromContractWithCustomerIncludingAssessedTax. Source concepts: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.

SGRY net income, last 5 periods. Source: SEC companyfacts FY2025.SGRY net income, last 5 periods. Source: SEC companyfacts FY2025.SGRY Net incomeLatest point: FY2025 = -$77.9MSource: SEC companyfacts FY2025.Fiscal yearNet income-$250.0M-$125.0M$0.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001638833-26-000008; filed 2026-03-02. Concept: NetIncomeLoss. Source concepts: us-gaap:NetIncomeLoss.

SGRY operating income, last 5 periods. Source: SEC companyfacts FY2025.SGRY operating income, last 5 periods. Source: SEC companyfacts FY2025.SGRY Operating incomeLatest point: FY2025 = $389.5MSource: SEC companyfacts FY2025.Fiscal yearOperating income$0.0B$250.0M$500.0MFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001638833-26-000008; filed 2026-03-02. Concept: OperatingIncomeLoss. Source concepts: us-gaap:OperatingIncomeLoss.

SGRY diluted eps, last 5 periods. Source: SEC companyfacts FY2025.SGRY diluted eps, last 5 periods. Source: SEC companyfacts FY2025.SGRY Diluted EPSLatest point: FY2025 = -$0.61/shareSource: SEC companyfacts FY2025.Fiscal yearDiluted EPS (USD/share)-$1.50/share-$0.75/share$0.00/shareFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001638833-26-000008; filed 2026-03-02. Concept: EarningsPerShareDiluted. Source concepts: us-gaap:EarningsPerShareDiluted.

SGRY operating cash flow, last 5 periods. Source: SEC companyfacts FY2025.SGRY operating cash flow, last 5 periods. Source: SEC companyfacts FY2025.SGRY Operating cash flowLatest point: FY2025 = $274.3MSource: SEC companyfacts FY2025.Fiscal yearOperating cash flow$0.0B$250.0M$500.0MFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001638833-26-000008; filed 2026-03-02. Concept: NetCashProvidedByUsedInOperatingActivities. Source concepts: us-gaap:NetCashProvidedByUsedInOperatingActivities.

SGRY capital expenditures, last 5 periods. Source: SEC companyfacts FY2025.SGRY capital expenditures, last 5 periods. Source: SEC companyfacts FY2025.SGRY Capital expendituresLatest point: FY2025 = $78.7MSource: SEC companyfacts FY2025.Fiscal yearCapital expenditures$0.0B$125.0M$250.0MFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001638833-26-000008; filed 2026-03-02. Concept: PaymentsToAcquirePropertyPlantAndEquipment. Source concepts: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

SGRY assets, last 5 periods. Source: SEC companyfacts FY2025.SGRY assets, last 5 periods. Source: SEC companyfacts FY2025.SGRY AssetsLatest point: FY2025 = $8.1BSource: SEC companyfacts FY2025.Fiscal yearAssets$0.0B$5.0B$10.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001638833-26-000008; filed 2026-03-02. Concept: Assets. Source concepts: us-gaap:Assets.

SGRY stockholders' equity, last 5 periods. Source: SEC companyfacts FY2025.SGRY stockholders' equity, last 5 periods. Source: SEC companyfacts FY2025.SGRY Stockholders' equityLatest point: FY2025 = $1.7BSource: SEC companyfacts FY2025.Fiscal yearStockholders' equity$0.0B$1.0B$2.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001638833-26-000008; filed 2026-03-02. Concept: StockholdersEquity. Source concepts: us-gaap:StockholdersEquity.

SGRY cash and cash equivalents, last 5 periods. Source: SEC companyfacts FY2025.SGRY cash and cash equivalents, last 5 periods. Source: SEC companyfacts FY2025.SGRY Cash and cash equivalentsLatest point: FY2025 = $239.9MSource: SEC companyfacts FY2025.Fiscal yearCash and cash equivalents$0.0B$250.0M$500.0MFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001638833-26-000008; filed 2026-03-02. Concept: CashAndCashEquivalentsAtCarryingValue. Source concepts: us-gaap:CashAndCashEquivalentsAtCarryingValue.

SGRY free cash flow, last 5 periods. Source: SEC companyfacts FY2025.SGRY free cash flow, last 5 periods. Source: SEC companyfacts FY2025.SGRY Free cash flowLatest point: FY2025 = $195.6MSource: SEC companyfacts FY2025.Fiscal yearFree cash flow$0.0B$125.0M$250.0MFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001638833-26-000008; filed 2026-03-02. Concept: NetCashProvidedByUsedInOperatingActivities - PaymentsToAcquirePropertyPlantAndEquipment. Source concepts: us-gaap:NetCashProvidedByUsedInOperatingActivities; us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

As-reported value updates

No tracked differences above grepcent's stated thresholds and capped precision rule were found between the earliest XBRL-filed value and the value currently on file for the standardized annual metrics grepcent tracks.

Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-08-10. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001638833.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

QuarterEnd DateRevenueNet IncomeDiluted EPSMethod
2022-Q32022-09-30-0.28reported discrete quarter
2023-Q12023-03-31-0.20reported discrete quarter
2023-Q22023-06-300.15reported discrete quarter
2023-Q32023-09-30674,100,000-4,900,000-0.04reported discrete quarter
2023-Q42023-12-31735,400,000-1,000,000derived Q4 = FY annual - nine-month YTD
2024-Q12024-03-31717,400,000-12,400,000-0.10reported discrete quarter
2024-Q22024-06-30762,100,000-15,500,000-0.12reported discrete quarter
2024-Q32024-09-30770,400,000-31,700,000-0.25reported discrete quarter
2024-Q42024-12-31864,400,000-108,500,000derived Q4 = FY annual - nine-month YTD
2025-Q12025-03-31776,000,000-37,700,000-0.30reported discrete quarter
2025-Q22025-06-30826,200,000-2,500,000-0.02reported discrete quarter
2025-Q32025-09-30821,500,000-22,700,000-0.18reported discrete quarter
2025-Q42025-12-31885,000,000-15,000,000derived Q4 = FY annual - nine-month YTD
2026-Q12026-03-31810,900,000-35,900,000-0.28reported discrete quarter
2026-Q22026-06-30848,900,000-15,000,000-0.12reported discrete quarter

Quarterly Charts

SGRY quarterly revenue, last 12 periods. Source: SEC companyfacts 2026-Q2.SGRY quarterly revenue, last 12 periods. Source: SEC companyfacts 2026-Q2.SGRY Quarterly RevenueLatest point: 2026-Q2 = $848.9MSource: SEC companyfacts 2026-Q2.Fiscal quarterQuarterly Revenue$0.0B$500.0M$1.0B2023-Q32023-Q42024-Q12024-Q22024-Q32024-Q42025-Q12025-Q22025-Q32025-Q42026-Q12026-Q2

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001638833-26-000077; filed 2026-08-10. Concept: RevenueFromContractWithCustomerIncludingAssessedTax. Source concepts: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.

SGRY quarterly net income, last 12 periods. Source: SEC companyfacts 2026-Q2.SGRY quarterly net income, last 12 periods. Source: SEC companyfacts 2026-Q2.SGRY Quarterly Net incomeLatest point: 2026-Q2 = -$15.0MSource: SEC companyfacts 2026-Q2.Fiscal quarterQuarterly Net income-$250.0M-$125.0M$0.0B2023-Q32023-Q42024-Q12024-Q22024-Q32024-Q42025-Q12025-Q22025-Q32025-Q42026-Q12026-Q2

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001638833-26-000077; filed 2026-08-10. Concept: NetIncomeLoss. Source concepts: us-gaap:NetIncomeLoss.

SGRY quarterly diluted eps, last 12 periods. Source: SEC companyfacts 2026-Q2.SGRY quarterly diluted eps, last 12 periods. Source: SEC companyfacts 2026-Q2.SGRY Quarterly Diluted EPSLatest point: 2026-Q2 = -$0.12/shareSource: SEC companyfacts 2026-Q2.Fiscal quarterQuarterly Diluted EPS (USD/share)-$0.50/share$0.00/share$0.50/share2022-Q32023-Q12023-Q22023-Q32024-Q12024-Q22024-Q32025-Q12025-Q22025-Q32026-Q12026-Q2

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001638833-26-000077; filed 2026-08-10. Concept: EarningsPerShareDiluted. Source concepts: us-gaap:EarningsPerShareDiluted.

Business

Read SGRY's verbatim Item 1 Business section from its latest 10-K: Business.

Risk Factors

Read SGRY's verbatim Item 1A Risk Factors from its latest 10-K: Risk Factors.

Latest quarter (10-Q)

Latest 10-Q source: 0001638833-26-000077.

Extracted structurally from real Item 2 body heading to real Item 3/4 boundary. Confidence: high. Filing date: 2026-08-10. Report date: 2026-06-30.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the condensed consolidated financial statements and related notes included elsewhere in this report and our 2025 Annual Report on Form 10-K. Unless the context otherwise indicates, the terms "Surgery Partners," "we," "us," "our" or the "Company," as used herein, refer to Surgery Partners, Inc. and its subsidiaries, and the term "affiliates" means direct and indirect subsidiaries of Surgery Partners, Inc. and partnerships and joint ventures in which such subsidiaries are partners. The terms "facilities" or "hospitals" refer to entities owned and operated by affiliates of Surgery Partners, Inc. and the term "employees" refers to employees of affiliates of Surgery Partners, Inc.

Cautionary Note Regarding Forward-Looking Statements

This report contains forward-looking statements, which are based on our current expectations, estimates and assumptions about future events. All statements other than statements of current or historical fact contained in this report are forward-looking statements. These statements include, but are not limited to, statements regarding our future financial position, business strategy, budgets, effective tax rate, projected costs and plans and objectives of management for future operations. The words "projections," "believe," "continue," "drive," "estimate," "expect," "intend," "may," "plan," "will," "could," "would" and similar expressions are generally intended to identify forward-looking statements.

By their nature, forward-looking statements involve risks, uncertainties and other factors that may cause actual results to differ from the expectations expressed in the statements. Many of these factors are beyond our ability to control or predict. These factors include, without limitation, the risk that the potential sale transaction of our ownership interests in Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health may not be completed in a timely manner or at all, including the risk that required physician, regulatory and other approvals and consents are not obtained, are delayed, or are obtained subject to conditions that are not anticipated; the failure to satisfy other closing conditions to the transaction; the possibility that the anticipated benefits of the sale to us are not realized as expected, the potential adverse effect of the announcement or pendency of the transaction on the market price of, or trading in, our securities and on our business relationships, operating results, and business generally, including the ability to retain key personnel; risks related to diverting management's attention from our ongoing business operations; the amount of costs, fees, expenses, and charges related to the sale transaction; potential litigation relating to the transaction that could be instituted against us or our affiliates, officers, or directors, and the effects of any outcomes related thereto; reductions in payments from government health care programs and private insurance payors, such as health maintenance organizations, preferred provider organizations, and other managed care organizations and employers; our ability to contract with private insurance payors; changes in our payor mix or surgical case mix; failure to maintain or develop relationships with physicians on beneficial or favorable terms, or at all; the impact of payor controls designed to reduce the number of surgical procedures; our efforts to integrate operations of acquired businesses and surgical facilities, attract new physician partners, or acquire additional surgical facilities; supply chain issues, including shortages or quality control issues with surgery-related products, equipment and medical supplies; competition for physicians, nurses, strategic relationships, acquisitions and managed care contracts; our ability to attract and retain qualified health care professionals; our ability to enforce non-compete restrictions against our physicians; our ability to manage material liabilities whether known or unknown incurred as a result of acquiring surgical facilities; the impact of current and future legislation and other health care public policy changes, and the effect of that legislation and other regulatory actions on our business; our ability to comply with current health care laws and regulations; the outcome of legal and regulatory proceedings that have been or may be brought against us; the impact of cybersecurity attacks or intrusions; changes in the regulatory, economic and other conditions of the states where our surgical facilities are located; our indebtedness; the social and economic impact of a pandemic, epidemic or outbreak of a contagious disease on our business; and the risks and uncertainties set forth under the heading "Risk Factors" in our 2025 Annual Report on Form 10-K and discussed from time to time in our reports filed with the Securities and Exchange Commission.

Considering these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this report may not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements. When you consider these forward-looking statements, you should keep in mind these risk factors and other cautionary statements in this report.

These forward-looking statements speak only as of the date made. Other than as required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events or otherwise.

Executive Overview

As of June 30, 2026, we owned or operated, primarily in partnership with physicians, a portfolio of 178 surgical facilities comprised of 159 ASCs and 19 surgical hospitals across 30 states. We owned a majority interest in 87 of the surgical facilities and consolidated 120 of these facilities for financial reporting purposes.

Total revenues for the second quarter of 2026 increased 2.7% to $848.9 million from $826.2 million in the second quarter of 2025. The increase in revenues was attributable to same-facility revenue growth in 2026. Days adjusted same-facility revenues for the second quarter of 2026 increased 5.0% from the second quarter of 2025, with a 4.8% increase in revenue per case and a 0.3% increase in same-facility cases. Additionally, for the second quarter of 2026, net loss attributable to Surgery Partners, Inc. was $15.0 million compared to $2.5 million for the second quarter of 2025. For the second quarter of 2026, Adjusted EBITDA decreased 2.9% to $125.2 million compared to $129.0 million for the same period in 2025. A reconciliation of non-GAAP financial measures appears below under the heading "Certain Non-GAAP Measures."

We continue to focus on improving our same-facility performance, selectively acquiring established facilities, developing new facilities and pursuing other portfolio management initiatives.

18

Table of Contents

We had cash and cash equivalents of $216.7 million and $617.8 million of borrowing capacity under the Revolver as of June 30, 2026.

Revenues

Our revenues consist of patient service revenues and other service revenues. Patient service revenues consist of revenue from our Surgical Facilities reportable segment. Specifically, patient service revenues include fees for surgical or diagnostic procedures performed at surgical facilities that we consolidate for financial reporting purposes, as well as for patient visits to our physician practices, anesthesia services, pharmacy services and diagnostic screens ordered by our physicians. Other service revenues include management and administrative service fees derived from our non-consolidated facilities that we account for under the equity method, management of surgical facilities and physician practices in which we do not own an interest, management services we provide to physician practices for which we are not required to provide capital or additional assets and other non-patient services.

The following table summarizes revenues by service type as a percentage of total revenues:

Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Patient service revenues:
Patient service revenues97.3%97.3%97.5%97.5%
Other service revenues2.7%2.7%2.5%2.5%
Total revenues100.0%100.0%100.0%100.0%

Payor Mix

The following table sets forth by type of payor the percentage of our patient service revenues generated at the surgical facilities that we consolidate for financial reporting purposes:

Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Private insurance payors48.6%52.1%49.5%52.0%
Government payors46.1%42.9%45.6%43.1%
Self-pay payors2.8%2.7%2.6%2.7%
Other payors (1)2.5%2.3%2.3%2.2%
Total100.0%100.0%100.0%100.0%

(1)Comprised of automobile liability, letters of protection and other payor types.

Surgical Case Mix

We primarily operate multi-specialty surgical facilities where physicians perform a variety of procedures in various specialties. We believe this diversification helps to protect us from adverse pricing and utilization trends in any individual procedure type and results in greater consistency in our case volume.

The following table sets forth the percentage of cases in each specialty performed at the surgical facilities that we consolidate for financial reporting purposes for the periods indicated:

Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Orthopedics and pain management40.1%39.8%40.6%40.2%
Ophthalmology20.8%22.2%20.7%22.1%
Gastrointestinal23.7%24.8%23.7%24.6%
General surgery1.9%1.8%1.9%2.0%
Other13.5%11.4%13.1%11.1%
Total100.0%100.0%100.0%100.0%

19

Table of Contents

Critical Accounting Policies

A summary of significant accounting policies is disclosed in our 2025 Annual Report on Form 10-K under the caption “Critical Accounting Policies” in the Management’s Discussion and Analysis of Financial Condition and Results of Operations section. There have been no material changes in the nature of our critical accounting policies or the application of those policies since December 31, 2025.

Results of Operations

Comparison of Operating Results for the Three Months Ended June 30, 2026 to the Three Months Ended June 30, 2025

The following tables summarize certain results from the condensed consolidated statements of operations for the periods indicated (in millions):

[Excerpt truncated for page length; source filing is linked above.]

Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: 0001638833-26-000008. The complete FY 2025 MD&A is published at /company/SGRY/mda/fy2025/.

Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary. Confidence: high. Filing date: 2026-03-02. Report date: 2025-12-31.

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our audited consolidated financial statements and related notes included elsewhere in this Annual Report. This discussion contains forward-looking statements that involve risks and uncertainties. For additional information regarding certain of the risks and uncertainties that affect our business and the industry in which we operate, please see Item 1A. "Risk Factors" and Item 9A. "Controls and Procedures" found elsewhere in this Annual Report. Unless the context otherwise indicates, the terms "Surgery Partners," "we," "us," "our" or the "Company," as used herein, refer to Surgery Partners, Inc. and its subsidiaries. Unless the context implies otherwise, the term "affiliates" means direct and indirect subsidiaries of Surgery Partners, Inc. and partnerships and joint ventures in which such subsidiaries are partners. The terms "facilities" or "hospitals" refer to entities owned and operated by affiliates of Surgery Partners, Inc. and the term "employees" refers to employees of affiliates of Surgery Partners, Inc.

Executive Overview

As of December 31, 2025, we owned or operated, primarily in partnership with physicians, a portfolio of 176 surgical facilities comprised of 157 ASCs and 19 surgical hospitals across 30 states. We owned a majority interest in 90 of the surgical facilities and consolidated 121 of these facilities for financial reporting purposes.

Total revenues for 2025 increased 6.2% to $3.3 billion from $3.1 billion in 2024. The increase in revenues was attributable to same-facility revenue growth and the net impact from acquisitions and divestitures completed in 2025. Days adjusted same-facility revenues for 2025 increased 4.9% from 2024, with a 1.4% increase in revenue per case and a 3.4% increase in same-facility cases. Additionally, for 2025, net loss attributable to Surgery Partners, Inc. was $77.9 million compared to $168.1 million for 2024. For 2025, Adjusted EBITDA increased 3.5% to $526.2 million compared to $508.2 million for 2024. The increase in Adjusted EBITDA was primarily attributable to revenue growth, continued cost management initiatives and acquisitions completed since the prior year. A reconciliation of non-GAAP financial measures appears below under the heading "Certain Non-GAAP Measures."

We continue to focus on improving our same-facility performance, selectively acquiring established facilities, developing new facilities and pursuing other portfolio management initiatives. During 2025, we acquired a controlling interest in twelve surgical facilities and several physician practices and other ancillary businesses for aggregate cash consideration of $162.1 million, net of cash acquired.

We had cash and cash equivalents of $239.9 million and $692.8 million of borrowing capacity under the Revolver as of December 31, 2025.

Recent Legislation

On July 4, 2025, Congress passed the One Big Beautiful Bill Act (the “OBBBA”), which introduced significant changes to federally funded healthcare programs, including Medicaid, Medicare, and the Affordable Care Act. While such changes are projected to reduce overall healthcare spending and increase regulatory burdens in certain jurisdictions in which the Company operates, they are not expected to materially impact the Company's financial statements.

The OBBBA also makes permanent key elements of the Tax Cuts and Jobs Act including, among others, 100% bonus depreciation and the business interest expense limitations. The Company’s tax provision for the year ended December 31, 2025, incorporates the effects of these tax law changes.

Revenues

Our revenues consist of patient service revenues and other service revenues. Patient service revenues consist of revenue from our Surgical Facilities reportable segment. Specifically, patient service revenues include fees for surgical or diagnostic procedures performed at surgical facilities that we consolidate for financial reporting purposes, as well as for patient visits to our physician practices, anesthesia services, pharmacy services and diagnostic screens ordered by our physicians. Other service revenues include management and administrative service fees derived from our non-consolidated facilities that we account for under the equity method, management of

30

Table of Contents

surgical facilities and physician practices in which we do not own an interest, management services we provide to physician practices for which we are not required to provide capital or additional assets and other non-patient services.

The following table summarizes revenues by service type as a percentage of total revenues:

Year Ended December 31,
202520242023
Patient service revenues:
Patient service revenues97.5%98.1%98.4%
Other service revenues2.5%1.9%1.6%
Total revenues100.0%100.0%100.0%

Payor Mix

The following table sets forth by type of payor the percentage of our patient service revenues generated at the surgical facilities that we consolidate for financial reporting purposes:

Year Ended December 31,
202520242023
Private insurance payors52.3%53.5%52.5%
Government payors42.8%41.1%41.8%
Self-pay payors2.7%2.7%2.5%
Other payors (1)2.2%2.7%3.2%
Total100.0%100.0%100.0%

(1)Comprised of automobile liability, letters of protection and other payor types.

Surgical Case Mix

We primarily operate multi-specialty surgical facilities where physicians perform a variety of procedures in various specialties. We believe this diversification helps to protect us from adverse pricing and utilization trends in any individual procedure type and results in greater consistency in our case volume.

The following table sets forth the percentage of cases in each specialty performed at the surgical facilities that we consolidate for financial reporting purposes for the periods indicated:

Year Ended December 31,
202520242023
Orthopedics and pain management40.7%40.2%36.1%
Ophthalmology21.7%23.3%24.4%
Gastrointestinal24.4%22.6%23.7%
General surgery1.9%2.3%2.6%
Other11.3%11.6%13.2%
Total100.0%100.0%100.0%

31

Table of Contents

Segment Information

Our business is comprised of one reportable segment, Surgical Facilities. For more information about the components of the reportable segment, please see Part I, Item 1. "Business-Operations" included elsewhere in this Annual Report. The "All other" line item below primarily consists of amounts attributable to the Company's corporate general and administrative functions.

The following tables present financial information for the reportable segment (in millions):

Year Ended December 31,
202520242023
Revenues:
Surgical Facilities$3,308.7$3,114.3$2,743.3
Total revenues$3,308.7$3,114.3$2,743.3
Adjusted EBITDA:
Surgical Facilities$626.7$610.0$534.3
All Other(100.5)(101.8)(96.2)
Total Adjusted EBITDA (1)$526.2$508.2$438.1
Depreciation and amortization:
Surgical Facilities$164.8$138.9$110.8
All other11.213.77.3
Total depreciation and amortization expense$176.0$152.6$118.1
Supplemental Information:
Cash purchases of property and equipment, net:
Surgical Facilities$77.9$86.6$88.7
All Other0.83.80.1
Total cash purchases of property and equipment, net$78.7$90.4$88.8

(1)For a reconciliation of Adjusted EBITDA to income before income taxes as reflected in the audited consolidated statements of operations see "Certain Non-GAAP Measures" below.

December 31,
20252024
Assets:
Surgical Facilities$7,643.9$7,466.3
All Other475.8423.7
Total assets$8,119.7$7,890.0

Critical Accounting Policies

In preparing our consolidated financial statements in conformity with U.S. Generally Accepted Accounting Principles ("GAAP"), we must use estimates and assumptions that affect the reported amounts of assets and liabilities and related disclosures and the reported amounts of revenue and expenses. In general, our estimates are based on historical experience and various other assumptions we believe are reasonable under the circumstances. We evaluate our estimates on an ongoing basis and make changes to the estimates and related disclosures as experience develops or new information becomes known. Actual results could differ from those estimates.

We consider our critical accounting policies to be those that involve significant judgments and uncertainties, and may potentially result in materially different results under different assumptions and conditions.

Revenue Recognition

Our patient service revenues are derived primarily from surgical procedures performed at our surgical facilities, patient visits to physician practices, anesthesia services provided to patients, pharmacy services and diagnostic screens ordered by our physicians. The fees for such services are billed either to the patient or a third-party payor, including Medicare and Medicaid. We recognize patient service

32

Table of Contents

revenues, net of contractual adjustments and implicit price concessions. Contractual adjustments and implicit price concessions are estimated based on contractual agreements, discount policies and historical experience of cash collections and historical write-offs. The estimated contractual adjustments are recognized at the time of services being performed, with ASCs typically based on contractual agreements and surgical hospitals typically based on historical experience of cash collections and write-offs. Changes in estimated contractual adjustments are recorded in the period of change, with final adjustments, if any, typically at the time of payment.

Other service revenues consist of management and administrative service fees derived from non-consolidated surgical facilities that we account for under the equity method, management of surgical facilities in which we do not own an interest and management services we provide to physician networks for which we are not required to provide capital or additional assets. The fees we derive from these management arrangements are generally based on a predetermined percentage of the revenues of each surgical facility and physician network. We recognize other service revenues in the period in which services are rendered and billed.

There were no material impacts on our financial condition or results of operations due to changes in assumptions or conditions related to revenue recognition during the years ended December 31, 2025, 2024 and 2023.

Accounts Receivable

[Excerpt truncated for page length; the complete text is on the linked full-MD&A page.]

Read the full FY 2025 MD&A or browse all MD&A years.

MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

Macro cross-references for SGRY

Indicators mapped to this company's SIC classification (industry 8062 Services-General Medical & Surgical Hospitals, NEC) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

Macro-to-micro threads including this sector: US labor market, Growth & output, Government finances, Sector employment.

All 71 macro indicators →

For LLMs & downloads

Markdown twin: /company/SGRY.md · JSON record: /company/SGRY.json · verified financials: JSON / CSV · machine TOC for the whole site: /llms.txt